FDA Extends Decision Date for TransCon CNP in Pediatric Achondroplasia by Three Months

The FDA has extended the decision date for Ascendis Pharma's TransCon CNP, a proposed treatment for children with achondroplasia, by three months to February 28, 2026. The decision was pushed back as the FDA needs more time to evaluate post-marketing requirement information. TransCon CNP is designed to be administered as a once-weekly subcutaneous injection, potentially offering a convenient treatment option.